COMPOUND RECORD / EMBRYONIC-NEURAL-PROTEIN-COMPLEX
Embryonic neural protein–polypeptide complexБелково-полипептидный комплекс из эмбриональной нервной ткани
PerformanceStressRecovery
Source linked
01 / OVERVIEW
About Embryonic neural protein–polypeptide complex
Names in this research collection
RU2485132C2
An ungulate embryonic neural-tissue complex. Its patent also describes a nucleotide-containing composition.
Research background
An ungulate embryonic neural-tissue complex. Its patent also describes a nucleotide-containing composition.
What the studies found
The linked records do not yet support a study-level summary for this preparation. Original publications require verification; additional research may exist.
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH
Understanding the evidence
Human research
Clinical effects are unverified.
Study methods
Patent manufacturing and analytical specification.
Independent replication
Independent replication is not established in the linked sources.
Source access
Original sources and the exact review scope are linked below.
Safety evidence
The linked experiments do not establish a safe human performance regimen.
Open a topic for the evidence assessment.
More findings, background and historyEVIDENCE REVIEW / 6 OCTOBER 2026
Outstanding review questions
Recover and appraise original experiments behind the review, patent or bibliographic trail.
No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2013 · RU2485132C2 · RU2485132C2: Embryonic neural protein–polypeptide complexFormulation · 34/36 after injected complex versus 9/24 untreated controls
Reported findings
Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
Example 11 · rat survival after bilateral carotid ligation
34/36 after injected complex versus 9/24 untreated controlsIntraperitoneal 0.2 mg/kg at one and five hours, as described. Applicant reports p≤0.01 versus control.
Example 11 · intranasal count conflict
Narrative 30/36 survivors; Table 1 prints 32/36 with 6 deaths and 83%The nasal arm cannot be reconciled from the filing. Timing and exposure also differ from the injected arm.
Formulation. Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
Separately manufactured patent-defined product. Cortexin and Cerebrolysin are background comparators, and the filing does not establish equivalence to PPK-V.
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
A. B. Nazarenko, M. A. Sokolov · RU2485132C2 · patent family 47259597
Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
Findings, study figures and available tables
Reported patent results
Reported findings
Ungulate embryonic neural-tissue protein–polypeptide complex and a composition containing nucleotide material.
Applicant characterization and supporting test disclosures. Analytical claim parameters are distinguishable from experiment outcomes.
Reported findings and study figures · Original patent, selected methods and examples checked
Measure
Result
Comparison, timing and statistics
Example 11 · rat survival after bilateral carotid ligation
34/36 after injected complex versus 9/24 untreated controls
Intraperitoneal 0.2 mg/kg at one and five hours, as described. Applicant reports p≤0.01 versus control.
Example 11 · intranasal count conflict
Narrative 30/36 survivors; Table 1 prints 32/36 with 6 deaths and 83%
The nasal arm cannot be reconciled from the filing. Timing and exposure also differ from the injected arm.
Protein–polypeptide range
0.5–200 kDa, with ≥70% in 20–160 kDa range
Claimed composition and characterization specification.
Separate nucleotide component
12–1,000 kDa as printed
The pharmaceutical composition includes a separate nucleotide fraction. No clinical effect inferred.
Separately manufactured patent-defined product. Cortexin and Cerebrolysin are background comparators, and the filing does not establish equivalence to PPK-V.
Applicant characterization and supporting test disclosures. Analytical claim parameters are distinguishable from experiment outcomes.
What was checked
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Limitations & review scope
Separately manufactured patent-defined product. Cortexin and Cerebrolysin are background comparators, and the filing does not establish equivalence to PPK-V.
Separately manufactured patent-defined product. Cortexin and Cerebrolysin are background comparators, and the filing does not establish equivalence to PPK-V.
Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Source checked 2026-11-09. See the review scope above for the material assessed.